CJC-1295 No DAC: Short-Acting GHRH Analogue Research Compound

Global Peptides supplies research grade CJC-1295 No DAC to laboratories across Australia, supporting studies into pulsatile growth hormone signalling and GHRH receptor research.

CJC-1295 No DAC, also known as Modified GRF 1-29, is a synthetic 29 amino acid analogue of growth hormone releasing hormone carrying four amino acid substitutions that improve resistance to enzymatic breakdown. It lacks the Drug Affinity Complex linker, so it does not bind serum albumin and remains active for only a short window in laboratory models.

Each batch is produced under controlled manufacturing conditions and undergoes independent laboratory verification, supporting consistent, repeatable results across analytical testing. A Certificate of Analysis is available on request for every order.

What is CJC-1295 No DAC?

Researchers often ask how this compound differs from the longer acting version of the same analogue.

The key distinction is the absence of the Drug Affinity Complex. Without it, the molecule clears from circulation quickly, producing brief bursts of receptor activity in experimental systems rather than the prolonged stimulation associated with the conjugated form.

This brief activity profile makes the compound a useful reference in research comparing short pulse signalling against sustained GHRH receptor stimulation in the anterior pituitary.

Research Areas Explored With CJC-1295 No DAC

Within controlled laboratory settings, research connected to this compound commonly looks at areas such as:

• Pulsatile growth hormone release dynamics
• GHRH receptor activation in pituitary models
• Comparative research against the longer acting DAC version
• Short half-life peptide pharmacology
• Endocrine and metabolic pathway modelling

These points reflect laboratory observation only and are not intended as claims about therapeutic outcomes.

Research Areas of Interest

• Studies into pulse based GHRH receptor signalling
• Investigation of the growth hormone and IGF-1 axis
• Comparative GHRH analogue pharmacology
• Endocrine regulation modelling

Product Information

• Compound: CJC-1295 No DAC (Modified GRF 1-29)
• Classification: Short acting GHRH analogue
• Sequence length: 29 amino acids
• Key feature: No Drug Affinity Complex linker
• Form: Lyophilised powder
• Purity level: 98% or above (HPLC verified)
• Testing: Independent third-party laboratory verification, CoA available on request
• Storage: Store refrigerated after reconstitution

Why Researchers Reference CJC-1295 No DAC

Laboratories studying GHRH signalling frequently reference this compound because its short activity window lets pulse dynamics be examined without the lingering receptor stimulation seen with albumin bound versions. It also offers a clear comparison point against the Drug Affinity Complex form within the same analogue family.

Researchers comparing options across related compounds can explore the full peptides category for additional research materials.

CJC-1295 No DAC Australia Supply

Laboratories can source verified material through Global Peptides, supported by transparent documentation and confirmed purity levels for every batch.

Researchers who buy CJC 1295 No DAC for laboratory projects gain access to batch specific Certificates of Analysis, HPLC and LC-MS verification, and secure ordering processes designed for research institutions.

Global Peptides offers fast nationwide shipping and dedicated support for research enquiries, and researchers can browse our catalog to view other research compounds available alongside this analogue.

Research Use Only

This compound is supplied strictly for laboratory and scientific research purposes and is not approved for consumption, therapeutic use or clinical application outside of a qualified research setting.